March 30, 2018

Entos and Oisin Bio Announce Fusogenix License for SENSOlytics™

Published by:
Entos Pharmaceuticals

Oisin Biotechnologies Uses Entos’ Fusogenix LNP Platform in their ground-breaking SENSOlytics™ technology

June 2018: Targeting and destroying senescent cells with a senolytic drug that leaves all other cells undamaged, may be the most effective way to dramatically increase the human health span and lifespan. OisinBiotechnologies has a novel, programmable senolytic suicide gene therapy, but no way to safely administer it using currently available delivery methods. Entos has a novel delivery nanoparticle with a patented fusogenic protein formulation promoting highly effective fusion with target cells, that is well-tolerated and has a wide biodistribution in vivo.

With the licensing deal in place, Entos and Oisin combined these two technologies to create Oisin’s proprietary SENSOlytics™ platform; a highly efficient, precise targeting of senescent cells based on their unique gene expression profile. The SENSOlytics™ suicide gene therapy has proven to be well-tolerated, can be dosed repeatedly at high concentrations, and can target extra-hepatic regions, as well as the liver.

Read an interview with Gary Hudson, CEO ofOisin.

Link: https://medium.com/@arielf/the-rise-of-oisin-d4664ed7e9

Listen to Stephen Hilbert, head of corporate development for Oisin Biotechnologies, talk at the Ending Age-Related Diseases 2018 conference at the Cooper Union, New York City.

BACK TO NEWS & PUBLICATIONS
Entos Pharmaceuticals
Unit 4550, 10230 Jasper Avenue
Edmonton, Alberta, Canada
T5J 4P6

Email: info@entospharma.com
Phone: 1-780-862-7445
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.